Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GLYC)

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Business Wire March 27, 2024

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Business Wire March 13, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Business Wire February 26, 2024

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire February 12, 2024

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Business Wire January 4, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewswire January 3, 2024

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Business Wire December 10, 2023

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Business Wire November 9, 2023

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Business Wire November 3, 2023
View More News ››

Opinion & Analysis (NDAQ:GLYC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GLYC)

Apollomics Completes Enrollment in Phase 3 Bridging Study of

News; $GLYC Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute...
whytestocks - January 3, 2024
View more Bullboard ››

Prospera Energy Inc

Prospera Energy Inc

Prospera Energy Inc. is a Canada-based energy company. The Company specializes in the exploration, development, and ...
View More »